- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 31, 2024
Product Development
Immunotherapies break into cold colorectal cancers at ASCO
Data from Regeneron, Agenus and others highlight immuno-oncology progress in genetically stable colorectal cancer
BioCentury | Apr 27, 2024
Discovery & Translation
Science spotlight: Tumor T cell restriction mechanism, plus programmable RNA excision
BioCentury’s roundup of translational innovations
BioCentury | Dec 22, 2023
Distillery Therapeutics
Reprogramming IL-1β-expressing macrophages for pancreatic cancer
BioCentury | Sep 27, 2022
Finance
Sept. 26 Quick Takes: Prime Medicine is next biotech to test IPO market
Plus FDA guidances on pediatric trials, naloxone products and updates from Santen-Ube, Brii
BioCentury | Oct 1, 2021
Translation in Brief
Mapping protein interaction networks to uncover new cancer targets
Plus: OncoCyte, MISER, GSK and more
BioCentury | Mar 30, 2021
Deals
March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest
SomaLogic Inc. is merging with CM Life Sciences II, a SPAC sponsored by Casdin Capital and Corvex Management (NASDAQ:CMIIU). The deal is expected to give the proteomics company up to $651 million
BioCentury | Dec 12, 2020
Translation in Brief
Fecal transplant improves checkpoint inhibitor response in Phase I; plus Secarna’s antitumor antisense oligos, a blood-based mRNA test for Alzheimer’s and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 98